Cencora Raises 2025 Profit Forecast Amid Strong Specialty Drug Demand

Cencora, formerly known as AmerisourceBergen, reported a significant revenue increase of 12.8% year-over-year for the first quarter of fiscal 2025, reaching $81.5 billion, driven by strong sales of specialty medicines and GLP-1 drugs. The company raised its adjusted earnings per share (EPS) guidance for the year to a range of $15.25 to $15.55, reflecting robust performance and strategic acquisitions, including Retina Consultants of America. Despite a decrease in GAAP diluted EPS due to operating costs, Cencora's adjusted EPS of $3.73 exceeded analyst expectations of $3.50. The U.S. healthcare solutions segment saw a notable 14% revenue gain, bolstered by increased demand for medications addressing complex conditions. Cencora's focus on specialty services and customer-centric strategies has positioned it favorably in the healthcare market. Analysts remain optimistic about Cencora's growth potential, with projected revenue growth of 8% to 10% for the full fiscal year.